Zhang Ying, Jenkins Alicia J, Basu Arpita, Stoner Julie A, Lopes-Virella Maria F, Klein Richard L, Lyons Timothy J
Department of Biostatistics and Epidemiology University of Oklahoma Health Sciences Center, Oklahoma City, OK.
National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Sydney, NSW, Australia Centre for Experimental Medicine, Queen's University of Belfast, Northern Ireland, UK.
J Lipid Res. 2016 Feb;57(2):310-7. doi: 10.1194/jlr.P060657. Epub 2015 Dec 9.
Our objective is to define differences in circulating lipoprotein subclasses between intensive versus conventional management of type 1 diabetes during the randomization phase of the Diabetes Control and Complications Trial (DCCT). NMR-determined lipoprotein subclass profiles (NMR-LSPs), which estimate molar subclass concentrations and mean particle diameters, were determined in 1,294 DCCT subjects after a median of 5 years (interquartile range: 4-6 years) of randomization to intensive or conventional diabetes management. In cross-sectional analyses, we compared standard lipids and NMR-LSPs between treatment groups. Standard total, LDL, and HDL cholesterol levels were similar between randomization groups, while triglyceride levels were lower in the intensively treated group. NMR-LSPs showed that intensive therapy was associated with larger LDL diameter (20.7 vs. 20.6 nm, P = 0.01) and lower levels of small LDL (median: 465 vs. 552 nmol/l, P = 0.007), total IDL/LDL (mean: 1,000 vs. 1,053 nmol/l, P = 0.01), and small HDL (mean: 17.3 vs. 18.6 μmol/l, P < 0.0001), the latter accounting for reduced total HDL (mean: 33.8 vs. 34.8 μmol/l, P = 0.01). In conclusion, intensive diabetes therapy was associated with potentially favorable changes in LDL and HDL subclasses in sera. Further research will determine whether these changes contribute to the beneficial effects of intensive diabetes management on vascular complications.
我们的目标是在糖尿病控制与并发症试验(DCCT)的随机分组阶段,明确1型糖尿病强化治疗与传统治疗在循环脂蛋白亚类方面的差异。在1294名DCCT受试者中,于随机分配至强化或传统糖尿病治疗方案后中位时间5年(四分位间距:4 - 6年)时,测定了通过核磁共振(NMR)确定的脂蛋白亚类谱(NMR-LSPs),该谱可估算亚类摩尔浓度及平均颗粒直径。在横断面分析中,我们比较了治疗组之间的标准血脂和NMR-LSPs。随机分组组之间的标准总胆固醇、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)胆固醇水平相似,而强化治疗组的甘油三酯水平较低。NMR-LSPs显示,强化治疗与更大的LDL直径(20.7对20.6纳米,P = 0.01)以及更低水平的小LDL(中位数:465对552纳摩尔/升,P = 0.007)、总中间密度脂蛋白/低密度脂蛋白(IDL/LDL,均值:1000对1053纳摩尔/升,P = 0.01)和小HDL(均值:17.3对18.6微摩尔/升,P < 0.0001)相关,后者导致总HDL降低(均值:33.8对34.8微摩尔/升,P = 0.01)。总之,强化糖尿病治疗与血清中LDL和HDL亚类的潜在有利变化相关。进一步研究将确定这些变化是否有助于强化糖尿病管理对血管并发症的有益作用。